近期,阿斯利康、施维雅、吉利德等跨国药企纷纷进行收购。阿斯利康收购EsoBiotec加速细胞治疗布局,施维雅收购小分子药物BN104以扩展血液恶性肿瘤产品组合,吉利德则收购免疫疗法和两款治疗性疫苗以加强HIV和HBV治疗领域的产品线。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.